GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ulisse Biomed SpA (MIL:UBM) » Definitions » Common Stock

Ulisse Biomed SpA (MIL:UBM) Common Stock : €0.25 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Ulisse Biomed SpA Common Stock?

Ulisse Biomed SpA's quarterly common stock increased from Dec. 2023 (€0.22 Mil) to Jun. 2024 (€0.22 Mil) and increased from Jun. 2024 (€0.22 Mil) to Dec. 2024 (€0.25 Mil).

Ulisse Biomed SpA's annual common stock increased from Dec. 2022 (€0.08 Mil) to Dec. 2023 (€0.22 Mil) and increased from Dec. 2023 (€0.22 Mil) to Dec. 2024 (€0.25 Mil).


Ulisse Biomed SpA Common Stock Historical Data

The historical data trend for Ulisse Biomed SpA's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ulisse Biomed SpA Common Stock Chart

Ulisse Biomed SpA Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Common Stock
Get a 7-Day Free Trial 0.05 0.08 0.08 0.22 0.25

Ulisse Biomed SpA Semi-Annual Data
Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.08 0.08 0.22 0.22 0.25

Ulisse Biomed SpA Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Ulisse Biomed SpA Business Description

Traded in Other Exchanges
N/A
Address
Area Science Park - SS14 km.163, 5, Basovizza, ITA, 34149
Ulisse Biomed SpA is a healthcare biotech company. It is engaged in developing medical diagnostics, theranostics, and therapeutics solutions. The company has three technology platforms, namely, Sagitta for molecular diagnostics, NanoHybrid for theranostics and diagnostics, and Aptavir for therapeutics.

Ulisse Biomed SpA Headlines

No Headlines